A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab

Trial Profile

A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Ewing's sarcoma; Neuroblastoma; Neuroectodermal tumours; Osteosarcoma; Rhabdomyosarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Initial results assessing the safety and antitumor activity of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 28 Sep 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top